ENTA at a glance
ENANTA PHARMACEUTICALS INC (ENTA, SEC CIK 1177648) filed its latest 10-K annual report on November 18, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as August 10, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended September 30, 2026 (FY2026), ENANTA PHARMACEUTICALS INC (ENTA) reported revenue of $63.0 million (down 3.6% from FY2025) and a net loss of $68.2 million. Diluted EPS was -$2.35.
- As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding ENANTA PHARMACEUTICALS INC (ENTA) shares worth $132.9 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $63.0M
- −3.6% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 25 funds
- $132.9M · −1 vs prior quarter
- Latest 8-K
- Nov 16, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $63.0M, down $2.3M YoY from $65.3M, due to lower AbbVie HCV sales
- Net loss $68.2M vs $81.9M, operating loss $62.4M vs $85.3M
- Best R&D performer: immunology $55.0M, up $11.2M; worst: virology $25.9M, down $33.9M
- Operating cash used $42.6M, financing cash provided $47.7M, liquidity $194.5M
- Outlook: funding expected into fiscal 2029; RSV trial spending expected to increase, clinical-development risk remains high
Business Overview
- Core model: Chemistry-driven discovery and development of wholly owned oral small-molecule drugs for viral and immunological diseases
- New 2026 advances: Zelicapavir entered registrational Phase 2b/3 RSV testing, while EDP-978 began Phase 1 for chronic spontaneous urticaria
- Pipeline expansion: MRGPRX2 program launched, EPS-5336 selected, and IND filing targeted for fourth quarter 2027
- Financial runway: $194.5 million in cash, equivalents and marketable securities, funding operations into fiscal 2029
- Notable filing-year milestone: Acute-HCV approval expanded MAVYRET/MAVIRET to the European Union in June 2026
Risk Factors
- Pfizer Paxlovid patent litigation: Federal Circuit affirmed invalidity in June 2026, Unified Patent Court invalidated European counterpart in October 2026
- China supply exposure: Key API intermediates and research rely on Chinese providers vulnerable to BIOSECURE Act restrictions, tariffs, sanctions and geopolitical disruption
- AbbVie royalty concentration: 54.5% of MAVYRET/MAVIRET royalties paid to OMERS through June 30, 2032
- HCV market disruption: Gilead’s authorized generic Epclusa and Harvoni, plus discounted Medicaid pricing, threaten MAVYRET/MAVIRET royalties
- Leadership transition: CEO Jay Luly plans retirement by February 1, 2027, with successor search underway amid a one-third workforce reduction in September 2026
AI summary of the ENTA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No material changes to risk factors identified in provided text
- Liquidity risk: $211,493 cash, cash equivalents, and marketable securities expected to fund operations for at least 12 months
- Financial risk: Royalty-sale liability $125,073 with 12.8% effective annual imputed interest rate
- Market risk: MAVYRET/MAVIRET royalties depend on AbbVie sales and face competition from other HCV treatments
- Regulatory risk: Product candidates require extensive clinical testing and regulatory approvals before commercialization
AI summary of the ENTA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Fiscal quarter and full-year results for period ended September 30, 2026
- Press release contains the substantive financial results and management commentary as Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Revenue $63.0M in fiscal 2026, down from $65.3M, reflecting declining AbbVie MAVYRET/MAVIRET royalties
- Cash and marketable securities $194.5M, with retained royalties expected to fund operations into fiscal 2029
Item 8.01: Other Events
- UPC invalidated Enanta’s EP 4 051 265 patent covering Pfizer’s Paxlovid activities
- Infringement claims against Pfizer were dismissed as unfounded across 18 participating EU member states
Item 7.01: Regulation FD Disclosure
- CEO Jay R. Luly, Ph.D. planned retirement, creating leadership-transition risk
- Tara L. Kieffer, Ph.D. appointed Chief Operating Officer, effective succession step
Item EX-99.1: Item EX-99.1
- CEO Jay R. Luly retiring by February 1, 2027 after 23 years leading Enanta
- Luly remains Strategic Advisor through 2027, supporting leadership continuity
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CEO Jay R. Luly, age 70, plans retirement by February 1, 2027 after 23 years leading Enanta
- Expected 2027 strategic-advisor role could support leadership transition continuity
AI summaries of ENTA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ENTA
Don't miss the next ENTA filing
- Alerts as it files. A push when ENTA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ENTA, by share count.
- Ask anything. An AI agent that reads every ENTA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Rottinghaus Scott T. | F | Aug 8, 2026 | 1,467 | $13.34 |
| CARTER BRUCE L A | A | Mar 11, 2026 | 20,000 | - |
| FOLETTA MARK G | A | Mar 11, 2026 | 20,000 | - |
| Hata Yujiro S | A | Mar 11, 2026 | 20,000 | - |
| Vance Terry | A | Mar 11, 2026 | 20,000 | - |
| Russell Lesley | A | Mar 11, 2026 | 20,000 | - |
| Peterson Kristine | A | Mar 11, 2026 | 20,000 | - |
| Kowalsky Matthew Paul | A | Feb 12, 2026 | 4,175 | - |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $65.3M | $63.0M |
| Operating Income | -$121.7M | -$85.3M | -$62.4M |
| Net Income | -$116.0M | -$81.9M | -$68.2M |
| Op. Margin | - | -130.7% | -99.0% |
| Net Margin | - | -125.4% | -108.3% |
| Balance Sheet | |||
| Total Assets | - | $280.7M | $275.6M |
| Equity | - | $64.7M | $80.2M |
| ROE | - | -126.5% | -85.1% |
| Per Share | |||
| EPS | - | $-3.84 | $-2.35 |
| Cash Flow | |||
| Operating CF | -$78.8M | -$19.3M | -$42.6M |
| CapEx | $17.9M | $12.9M | $206K |
Source: XBRL data in ENANTA PHARMACEUTICALS INC (ENTA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ENTA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 25 | $132.9M |
| Q2 2026 | 26 | $137.3M |
| Q1 2026 | 26 | $124.0M |
| Q4 2025 | 23 | $151.6M |
| Q3 2025 | 23 | $93.3M |
| Q2 2025 | 25 | $63.3M |
| Q1 2025 | 22 | $37.5M |
| Q4 2024 | 18 | $32.1M |
- BlackRock+638.8K (+20%)
- Millennium Management+130.8K (+20%)
- Citadel Advisors LLC+87.8K (+173%)
- Morgan Stanley+64.3K (+20%)
- D.E. Shaw & Co+23.4K (+68%)
- Renaissance Technologies LLC−84.6K (-15%)
- Goldman Sachs Group−36.1K (-8%)
- Vanguard Portfolio Management LLC−34.8K (-3%)
- AQR Capital Management−23.6K (-9%)
- Wells Fargo & Co−17.8K (-71%)
- FMR LLC (Fidelity)−29.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 188 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ENTA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-K | Nov 18, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 8-K | Oct 28, 2026 | - | Analysis | - |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 10, 2026 | - | - | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 8-K | Jul 2, 2026 | - | Analysis | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 8-K | Jun 18, 2026 | - | Analysis | - |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 11, 2026 | - | Analysis | |
| 8-K | Mar 26, 2026 | - | - | - |
| 4 | Mar 13, 2026 | - | - | - |
| 4 | Mar 13, 2026 | - | - | - |
| 4 | Mar 13, 2026 | - | - | - |
| 4 | Mar 13, 2026 | - | - | - |
| 4 | Mar 13, 2026 | - | - | - |
| 4 | Mar 13, 2026 | - | - | - |
| 8-K | Mar 12, 2026 | - | Analysis | - |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ENTA SEC filings: frequently asked questions
Which institutions hold ENTA stock?
As of September 30, 2026, the largest ENANTA PHARMACEUTICALS INC (ENTA) holders among the 13F filers tracked by SignalX were BlackRock ($51.2 million), Vanguard Capital Management LLC ($15.8 million), Vanguard Portfolio Management LLC ($12.9 million), Millennium Management ($10.2 million), State Street Corp ($7.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ENTA's revenue in fiscal year 2026?
For the fiscal year ended September 30, 2026 (FY2026), ENANTA PHARMACEUTICALS INC (ENTA) reported revenue of $63.0 million (down 3.6% from FY2025) and a net loss of $68.2 million. Diluted EPS was -$2.35. The figures come from the XBRL data in the 10-K.
What are the main risks in ENTA's latest 10-K?
In the 10-K filed November 18, 2026, ENANTA PHARMACEUTICALS INC (ENTA) flagged: Pfizer Paxlovid patent litigation: Federal Circuit affirmed invalidity in June 2026, Unified Patent Court invalidated European counterpart in October 2026. China supply exposure: Key API intermediates and research rely on Chinese providers vulnerable to BIOSECURE Act restrictions, tariffs, sanctions and geopolitical disruption. (AI summary of the Risk Factors section.)
What did ENTA report in its latest 8-K?
ENANTA PHARMACEUTICALS INC (ENTA) filed an 8-K on November 16, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Fiscal quarter and full-year results for period ended September 30, 2026.
What are the latest ENTA SEC filings?
ENANTA PHARMACEUTICALS INC (ENTA) filed its latest 10-K annual report on November 18, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on August 10, 2026.
What is ENTA's SEC CIK number?
ENANTA PHARMACEUTICALS INC (ENTA)'s SEC Central Index Key (CIK) is 1177648. EDGAR lists every ENTA filing under that number.
Ask anything about ENTA
The research agent reads ENTA's filings, financials, insider trades and 13F holders, then answers with sources.